سعر اكسيلون 9مجم 5 سم 4.5مجم/24 ساعة 30 لصقة 9.5 مجم/24 h 2024

Rivastigmine transdermal patch 9.5 mg/24 h (10 cm2, 18 mg rivastigmine) (Exelon, Novartis; made by LTS Lohmann), pack of 30 patches, per the sheet name.

• Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Population: AdultsEuropean Medicines Agency
• US: dementia of the Alzheimer's type (mild, moderate and severe) and mild-to-moderate dementia associated with Parkinson's disease.Population: AdultsDailyMed (U.S. NLM)

• Application site skin reactions (usually mild to moderate erythema) are the most frequent adverse reactions; the next most common are gastrointestinal, including nausea and vomiting.International label, same product · European Medicines Agency

• Hypersensitivity to rivastigmine, to other carbamate derivatives or to any of the excipients; previous history of application site reactions suggestive of allergic contact dermatitis with rivastigmine patch.International label, same product · European Medicines Agency

• Misuse and dosing errors (not removing the old patch, using multiple patches at the same time) have caused serious adverse reactions, some requiring hospitalisation and rarely death; patients and caregivers must be instructed on administration.International label, same product · European Medicines Agency
• Application site skin reactions are usually mild to moderate; allergic contact dermatitis should be suspected if reactions spread beyond the patch size, become more intense (erythema, oedema, papules, vesicles) or do not improve within 48 hours after removal — then discontinue.International label, same product · European Medicines Agency
• Gastrointestinal disorders such as nausea, vomiting and diarrhoea are dose-related and may occur when initiating treatment and/or increasing the dose, more commonly in women; dehydration from prolonged vomiting or diarrhoea can have serious outcomes and should be managed with IV fluids and dose reduction or discontinuation.International label, same product · European Medicines Agency

• Succinylcholine-type muscle relaxantsRivastigmine may exaggerate their effects during anaesthesia; caution in selecting anaesthetic agents; dose adjustment or temporary interruption may be considered.European Medicines Agency
• Other cholinomimetic substancesShould not be given concomitantly because of possible additive effects.European Medicines Agency
• Anticholinergic medicines (e.g. oxybutynin, tolterodine)Rivastigmine might interfere with their activity.European Medicines Agency

• In animals rivastigmine and/or metabolites crossed the placenta; no clinical data on exposed pregnancies; should not be used during pregnancy unless clearly necessary.International label, same product · European Medicines Agency
• Rivastigmine is excreted in animal milk and it is not known whether it is excreted in human milk; women on rivastigmine should not breast-feed.International label, same product · European Medicines Agency

English text not available for this section.